Lori Hazlehurst
Overview
Explore the profile of Lori Hazlehurst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu X, Li L, Nkwocha J, Kmieciak M, Shang S, Cowart L, et al.
Signal Transduct Target Ther
. 2025 Feb;
10(1):50.
PMID: 39924517
The importance of MCL-1 in leukemogenesis has prompted development of MCL-1 antagonists e.g., S63845, MIK665. However, their effectiveness in acute myeloid leukemia (AML) is limited by compensatory MCL-1 accumulation via...
2.
Susperreguy S, Yamashita M, Choi C, Liao Y, Burch L, Blankenship T, et al.
Proc Natl Acad Sci U S A
. 2024 Nov;
121(49):e2411389121.
PMID: 39602257
Using genetically engineered mice and cell lines derived from genetically engineered mice we show that depletion of ER delimited Ca stores activates heteromeric Ca entry (SOCE) channels formed obligatorily, but...
3.
Sudalagunta P, Canevarolo R, Meads M, Silva M, Zhao X, Cubitt C, et al.
Cancer Res
. 2024 Oct;
85(2):378-398.
PMID: 39476082
Several therapeutic agents have been approved for treating multiple myeloma, a cancer of bone marrow-resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes....
4.
Dembitz V, Lawson H, Burt R, Natani S, Philippe C, James S, et al.
Leukemia
. 2024 Aug;
38(11):2395-2409.
PMID: 39187579
Identification of specific and therapeutically actionable vulnerabilities, ideally present across multiple mutational backgrounds, is needed to improve acute myeloid leukemia (AML) patients' outcomes. We identify stearoyl-CoA desaturase (SCD), the key...
5.
Malla M, Deshmukh S, Wu S, Samec T, Olevian D, El Naili R, et al.
Cancer Gene Ther
. 2024 Aug;
31(10):1547-1558.
PMID: 39174744
The expression of the protein Mesothelin (MSLN) is highly variable in several malignancies, including colorectal cancer (CRC), and high levels are associated with aggressive clinicopathological features and worse patient survival....
6.
Malla M, Kumar Deshkmukh S, Wu S, Samec T, Olevian D, Naili R, et al.
Res Sq
. 2024 Jan;
PMID: 38234761
The expression of the protein is highly variable in several malignancies including colorectal cancer (CRC) and high levels are associated with aggressive clinicopathological features and worse patient survival. CRC is...
7.
Marr K, Gard J, Harryman W, Keeswood E, Paxson A, Wolgemuth C, et al.
Biophys J
. 2023 Sep;
122(21):4194-4206.
PMID: 37766428
Bladder, colon, gastric, prostate, and uterine cancers originate in organs surrounded by laminin-coated smooth muscle. In human prostate cancer, tumors that are organ confined, without extracapsular extension through muscle, have...
8.
Shultz C, Gates C, Petros W, Ross K, Veltri L, Craig M, et al.
Cancer Rep (Hoboken)
. 2022 Nov;
6(3):e1746.
PMID: 36382570
Background: Previous population health studies examining adults with acute myeloid leukemia (AML); however many of these, such as the Cancer Genome Atlas, are derived from databases collected by large urban...
9.
Caulfield T, Hayes K, Qiu Y, Coban M, Oh J, Lane A, et al.
Biomolecules
. 2020 Oct;
10(10).
PMID: 33027969
Chloroethylagelastatin A (CEAA) is an analogue of agelastatin A (AA), a natural alkaloid derived from a marine sponge. It is under development for therapeutic use against brain tumors as it...
10.
Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, et al.
Leuk Res
. 2018 Oct;
74:89-96.
PMID: 30340199
Purpose: Preclinical evidence indicates that the bone marrow microenvironment provides a protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL tyrosine kinase inhibitors (TKIs), but...